Navigation Links
Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
Date:10/17/2007

Takeda Will Continue to Dominate the Type 2 Diabetes Market, According to a

New Report from Decision Resources

WALTHAM, Mass., Oct. 17 /PRNewswire/ -- Decision Resources and Millennium Research Group have released a new report finding that Merck will obtain blockbuster antidiabetic drug sales in the type 2 diabetes market by 2011, thanks to uptake of their DPP-IV inhibitor, Januvia. Januvia will see rapid uptake as a second-and third-line agent in type 2 diabetes treatment and its success will propel Merck into the diabetes market, giving the company 15 percent of the market in 2011. Januvia will become the second-leading blockbuster in the market, behind only Takeda's Actos. Surveyed primary care physicians ranked Merck as best for product innovation.

"The choice of Merck as 'best' for product innovation in type 2 diabetes indicates physicians' enthusiasm for Januvia," said Elena Rossi, analyst at Millennium Research Group. "This enthusiasm is echoed by the 71 percent of surveyed physicians who believe that Merck will be one of the most influential companies in type 2 diabetes over the next five years."

The report also finds that Takeda led the type 2 diabetes drug market in 2006 with a market share of almost 30 percent from sales of the PPAR-gamma agonist Actos; however, this share will fall to about 21 percent in 2011 due to strong competition from the novel DPP-IV inhibitors (like Januvia) and GLP- 1 analogues (such as Eli Lilly/Amylin's Byetta). Nonetheless, the Actos franchise will continue to gain uptake in the market due in part to the launch of a novel fixed-dose combination of Actos with extended-release metformin. Furthermore, Takeda is developing a novel DPP-IV inhibitor, algoliptin, that is expected to launch in the United States and Europe in 2009 and provide strong competition for Januvia.

About Brands & Strategies

Brands & Strategies is the first and only report series to bring together all of the competitive information elements biopharmaceutical companies need to make informed decisions about their products and the best next-steps. Each report includes the following:

-- Physician perceptions of companies and brand attributes

-- Physician preference for sources of information

-- Physician opinion of future strategies, messaging, and upcoming events

-- Overview of competitive landscape

-- Pipeline analysis by company within a specific disease

-- SWOT analysis on each brand

-- Brand lifecycle strategy, including clinical trial competitive analysis

-- Trend analysis of brand-specific messaging

-- Brand-specific, event-driven, five-year annualized market forecast

-- Country-specific, event-driven market share projections by company and

brand

-- Drug class and brand vs. generics sales by country

-- Pricing analysis with company-specific strategy, price for all drugs

over five years, impact of generics

-- Analysis of promotional spend for each product

-- Selling strategies based on clinical trials

-- Prevalent and diagnosed population by country

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), part of the Decision Resources, Inc., family, is a leading provider of strategic information to the healthcare sector. Focused on the medical device, pharmaceutical, and biotechnology industries, the company provides clients its specialized industry expertise through published reports and customized consulting services.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Quality assurance of RNA derived from laser microdissected tissue samples obtained by the PALM MicroBeam System using the RNA 6000 Pico LabChip kit.
2. High Electrotransformation Efficiencies Obtained With DNA From Ligation Mixtures
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Though pharma growth slides, blockbusters reach new record
5. Jellyfish partners for sales tracking technology
6. Doyle wants sales tax applied to digital downloads
7. Mortgagebot builds online sales even as housing declines
8. Third Wave reports another loss, stronger sales
9. Johnson Controls reports record quarterly sales
10. Can sales outsourcing grow Wisconsin biotechs?
11. Sonic Foundry reports quarterly loss, higher Mediasite sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):